Radolfzell, Germany

Klaus Pekari

USPTO Granted Patents = 8 

Average Co-Inventor Count = 4.7

ph-index = 1


Location History:

  • Radolfzell, DE (2009 - 2010)
  • Mittelbiberach, DE (2010)

Company Filing History:


Years Active: 2009-2010

Loading Chart...
8 patents (USPTO):Explore Patents

Title: Klaus Pekari: Innovator in Anti-Proliferative Compounds

Introduction

Klaus Pekari is a notable inventor based in Radolfzell, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds with anti-proliferative and apoptosis-inducing activities. With a total of eight patents to his name, Pekari's work is recognized for its potential impact on cancer treatment.

Latest Patents

Among his latest patents are the Tetrahydropyridothiophenes, which are compounds of a specific formula. These compounds, in which Ra and Rb have the meanings indicated in the description, are novel effective compounds with anti-proliferative and/or apoptosis-inducing activity. This innovation highlights his commitment to advancing medical science and improving therapeutic options.

Career Highlights

Klaus Pekari is currently associated with 4SC AG, a company focused on developing innovative therapies for cancer and autoimmune diseases. His work at 4SC AG has positioned him as a key player in the pharmaceutical industry, contributing to groundbreaking research and development.

Collaborations

Pekari collaborates with talented professionals in his field, including Mathias Schmidt and Thomas Beckers. These partnerships enhance the research efforts and foster an environment of innovation and creativity.

Conclusion

Klaus Pekari's contributions to the field of pharmaceuticals through his patents and collaborations underscore his role as an influential inventor. His work continues to pave the way for advancements in cancer treatment and therapeutic development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…